US Commercialization

Macuject begins US Commercialization

Macuject is pleased to announce that we will run a pilot of our novel AMD platform at leading US optometry and ophthalmology partner sites during H1 2024.

With the support of ANDHealth+, this work will deliver valuable real-world clinical feedback, and generate the necessary data to commence the regulatory approval process with the FDA.

Just click the button and we’ll contact with you in the next few hours

Request a demo